nach oben

02.04.2024 | Review

Liver and Brain Disorders

verfasst von: Akash Roy, Uday Chand Ghoshal, Mahesh K. Goenka

Erschienen in: Current Hepatology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review provides a concise update on recent developments in liver and brain interactions traversing encephalopathy in acute, acute on chronic liver failure, and non-cirrhotic liver disease.

Recent Findings

An interconnected axis of gut-microbiota changes, systemic inflammation, and mediators of neuroinflammation impact liver-brain interaction. Encephalopathy in acute on chronic liver failure has its own trajectories. Newer drugs and techniques show promise, while established therapies have newer indications.

Summary

Neurogliovascular unit dysfunction and cross-talk abnormalities play an important role in brain dysfunction in liver disease. Ammonia is central to pathogenesis and has different implications in different settings of liver failure (acute/chronic/acute on chronic). Beyond cirrhosis, neurological dysfunction is common in non-cirrhotic portal hypertension, chronic viral hepatitis, and metabolic dysfunction associated steatotic liver disease. Newer therapies are promising, and future research should focus on further refinement of the pathophysiological basis for targeted therapies according to the type of encephalopathy.

Lewis M, Howdle PD. The neurology of liver failure. QJM An Int J Med [Internet]. 2003;96(9):623–33. https://doi.org/10.1093/qjmed/hcg110.CrossRef

Kheloufi L, Weiss N, Thabut D, Pais R. Neurocognitive impairment in obesity and liver disease—an unsolved mystery. Hepatol Commun [Internet]. 2023 [cited 2024 Jan 6];7(11). Available from: /pmc/articles/PMC10617873/

Nguyen HH, Swain MG. Avenues within the gut-liver-brain axis linking chronic liver disease and symptoms. Front Neurosci. 2023;17:1171253.

Louissaint J, Deutsch-Link S, Tapper EB. Changing epidemiology of cirrhosis and hepatic encephalopathy. Clin Gastroenterol Hepatol [Internet]. 2022 [cited 2024 Mar 12];20(8 Suppl):S1. Available from: /pmc/articles/PMC9531320/

Giri S, Singh A, Angadi S, Kolhe K, Roy A. Prevalence of hepatic encephalopathy in patients with non-cirrhotic portal hypertension: a systematic review and meta-analysis. Indian J Gastroenterol [Internet]. 2023;42(5):642–50. https://doi.org/10.1007/s12664-023-01412-1.CrossRefPubMed

Zheng K, Yoshida EM, Tacke F, Li Y, Guo X, Qi X. Risk of stroke in liver cirrhosis: a systematic review and meta-analysis. J Clin Gastroenterol. 2020;54(1):96–105.

Giménez-Garzó C, Fiorillo A, Ballester-Ferré MP, Gallego JJ, Casanova-Ferrer F, Urios A, et al. A new score unveils a high prevalence of mild cognitive impairment in patients with nonalcoholic fatty liver disease. J Clin Med [Internet]. 2021 [cited 2024 Mar 12];10(13):2806. Available from: https://www.mdpi.com/2077-0383/10/13/2806/htm

Banerjee A, Jana AK, Praharaj SK, Mukherjee D, Chakraborty S. Depression and anxiety in patients with chronic liver disease and their relationship with quality of life. Ann Indian Psychiatry. 2020;4(1):28–32.

Stone TW, Clanchy FIL, Huang YS, Chiang NY, Darlington LG, Williams RO. An integrated cytokine and kynurenine network as the basis of neuroimmune communication. Front Neurosci. 2022;24(16):1002004.CrossRef

10.

D’Mello C, Riazi K, Le T, Stevens KM, Wang A, McKay DM, et al. P-selectin-mediated monocyte-cerebral endothelium adhesive interactions link peripheral organ inflammation to sickness behaviors. J Neurosci [Internet]. 2013 [cited 2024 Jan 8];33(37):14878–88. Available from: https://pubmed.ncbi.nlm.nih.gov/24027287/

11.

Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. The cirrhosis dysbiosis ratio defines changes in the gut microbiome associated with cirrhosis and its complications. J Hepatol [Internet]. 2014 [cited 2024 Jan 11];60(5):940. Available from: /pmc/articles/PMC3995845/

12.

Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol [Internet]. 2012 [cited 2024 Jan 11];303(6). Available from: https://pubmed.ncbi.nlm.nih.gov/22821944/

13.

Butterworth RF. The liver–brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol 2013 109 [Internet]. 2013 2 [cited 2023 Dec 27];10(9):522–8. Available from: https://www.nature.com/articles/nrgastro.2013.99

14.

Mossad O, Erny D. The microbiota-microglia axis in central nervous system disorders. Brain Pathol [Internet]. 2020 [cited 2024 Jan 11];30(6):1159–77. Available from: https://pubmed.ncbi.nlm.nih.gov/33073887/

15.

Feng X, Li X, Zhang X, Chen W, Tian Y, Yang Q, et al. Hepatic encephalopathy in cirrhotic patients and risk of small intestinal bacterial overgrowth: a systematic review and meta-analysis. Biomed Res Int [Internet]. 2022 [cited 2023 Dec 26];2022. Available from: https://pubmed.ncbi.nlm.nih.gov/36303585/

16.

Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):965–77.

17.

Dohnalová L, Lundgren P, Carty JRE, Goldstein N, Wenski SL, Nanudorn P, et al. A microbiome-dependent gut-brain pathway regulates motivation for exercise. Nature [Internet]. 2022 [cited 2024 Jan 13];612(7941):739–47. Available from: https://pubmed.ncbi.nlm.nih.gov/36517598/

18.

Phillips GB, Schwartz R, Gabuzda GJ, Davidson CS. The syndrome of impending hepatic coma in patients with cirrhosis of the liver given certain nitrogenous substances. N Engl J Med [Internet]. 1952 [cited 2024 Jan 13];247(7):239–46. Available from: https://pubmed.ncbi.nlm.nih.gov/14947933/

19.

Wright G, Noiret L, Olde Damink SWM, Jalan R. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int [Internet]. 2011 [cited 2024 Jan 13];31(2):163–75. Available from: https://pubmed.ncbi.nlm.nih.gov/20673233/

20.

Butterworth RF. Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited. Metab Brain Dis [Internet]. 2016 [cited 2024 Jan 13];31(6):1211–5. Available from: https://pubmed.ncbi.nlm.nih.gov/26521983/

21.

Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut [Internet]. 2006 [cited 2024 Jan 14];55(1):98. Available from: /pmc/articles/PMC1856380/

22.

Li L, Liu P, Li K, Lin F, Ji CC, Wang YG, et al. Predictive value of blood ammonia in the prognosis of acute liver failure evaluated by receiver operating characteristic curves. Turkish J Gastroenterol [Internet]. 2021 [cited 2024 Jan 14];32(2):164. Available from: /pmc/articles/PMC8975305/

23.

Patwardhan VR, Jiang ZG, Risech-Neiman Y, Piatkowski G, Afdhal NH, Mukamal K, et al. Serum ammonia in associated with transplant-free survival in hospitalized patients with acutely decompensated cirrhosis. J Clin Gastroenterol. 2016;50(4):345–50.

24.

Vierling JM, Mokhtarani M, Brown RS, Mantry P, Rockey DC, Ghabril M, et al. Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis. Clin Gastroenterol Hepatol [Internet]. 2016 [cited 2024 Jan 13];14(6):903–906.e1. Available from: https://pubmed.ncbi.nlm.nih.gov/26707685/

25.

Jalan R, Rose CF. Heretical thoughts into hepatic encephalopathy. J Hepatol. 2022;77(2):539–48.CrossRefPubMed

26.

Shalimar, Sheikh MF, Mookerjee RP, Agarwal B, Acharya SK, Jalan R. Prognostic role of ammonia in patients with cirrhosis. Hepatology [Internet]. 2019 [cited 2024 Jan 14];70(3):982–94. Available from: https://pubmed.ncbi.nlm.nih.gov/30703853/

27.

Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol [Internet]. 2020 [cited 2024 Jan 13];73(6):1526–47. Available from: https://pubmed.ncbi.nlm.nih.gov/33097308/

28.

Mizuno K, Ueno Y. Autonomic nervous system and the liver. Hepatol Res [Internet]. 2017 [cited 2024 Jan 11];47(2):160–5. Available from: https://pubmed.ncbi.nlm.nih.gov/27272272/

29.

Teratani T, Mikami Y, Nakamoto N, Suzuki T, Harada Y, Okabayashi K, et al. The liver–brain–gut neural arc maintains the Treg cell niche in the gut. Nat. 2020;585(7826):591–6.

30.

Claeys W, Van Hoecke L, Lefere S, Geerts A, Verhelst X, Van Vlierberghe H, et al. The neurogliovascular unit in hepatic encephalopathy. JHEP Reports [Internet]. 2021 [cited 2024 Jan 8];3(5). Available from: /pmc/articles/PMC8476774/

31.

Yu X, Ji C, Shao A. Neurovascular unit dysfunction and neurodegenerative disorders. Front Neurosci [Internet]. 2020 [cited 2024 Jan 8];14. Available from: https://pubmed.ncbi.nlm.nih.gov/32410936/

32.

Ahmad A, Patel V, Xiao J, Khan MM. The role of neurovascular system in neurodegenerative diseases. Mol Neurobiol [Internet]. 2020 [cited 2024 Jan 8];57(11):4373–93. Available from: https://pubmed.ncbi.nlm.nih.gov/32725516/

33.

Butterworth RF. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. J Clin Exp Hepatol [Internet]. 2015 [cited 2024 Jan 14];5(Suppl 1):S96. Available from: /pmc/articles/PMC4442857/

34.

Stravitz RT, Fontana RJ, Karvellas C, Durkalski V, McGuire B, Rule JA, et al. Future directions in acute liver failure. Hepatology. 2023;78(4):1266–89.

35.

von Meijenfeldt FA, Stravitz RT, Zhang J, Adelmeijer J, Zen Y, Durkalski V, et al. Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome. Hepatology [Internet]. 2022;75(3):623–33. https://doi.org/10.1002/hep.32174.CrossRef

36.

Kolodziejczyk AA, Federici S, Zmora N, Mohapatra G, Dori-Bachash M, Hornstein S, et al. Acute liver failure is regulated by MYC- and microbiome-dependent programs. Nat Med 2020 2612 [Internet]. 2020 [cited 2024 Jan 14];26(12):1899–911. Available from: https://www.nature.com/articles/s41591-020-1102-2

37.

Anand AC, Nandi B, Acharya SK, Arora A, Babu S, Batra Y, et al. Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis. J Clin Exp Hepatol [Internet]. 2020 [cited 2024 Jan 14];10(4):339–76. Available from: https://pubmed.ncbi.nlm.nih.gov/32655238/

38.

Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol. 2016;14(8):1199-1206.e2.CrossRefPubMedPubMedCentral

39.

Rakela JL, Karvellas CJ, Koch DG, Vegunta S, Lee WM. Acute liver failure: biomarkers evaluated by the acute liver failure study group. Clin Transl Gastroenterol. 2023;14(4):e00565.

40.

Rajajee V, Vanaman M, Fletcher JJ, Jacobs TL. Optic nerve ultrasound for the detection of raised intracranial pressure. Neurocrit Care [Internet]. 2011;15(3):506–15. https://doi.org/10.1007/s12028-011-9606-8.CrossRefPubMed

41.

Vijay P, Lal BB, Sood V, Khanna R, Patidar Y, Alam S. Dynamic Optic Nerve Sheath Diameter (ONSD) guided management of raised intracranial pressure in pediatric acute liver failure. Hepatol Int [Internet]. 2021 [cited 2024 Jan 14];15(2):502–9. Available from: https://pubmed.ncbi.nlm.nih.gov/33625660/

42.

Kalal CR, Maiwall R, Choudhary A, Premkumar M, Kumar G, Vyas AK, et al. Mannitol is comparable to hypertonic saline for raised intracranial pressure in acute liver failure (MAHAL Study): a randomized controlled trial. Dig Dis [Internet]. 2022;40(5):607–15. https://doi.org/10.1159/000520229.CrossRefPubMed

43.

Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol [Internet]. 2016 [cited 2024 Jan 14];64(1):69–78. Available from: https://pubmed.ncbi.nlm.nih.gov/26325537/

44.

Maiwall R, Bajpai M, Singh A, Agarwal T, Kumar G, Bharadwaj A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: a randomized controlled trial. Clin Gastroenterol Hepatol. 2022;20(4):e831–54.CrossRefPubMed

45.

Warrillow S, Fisher C, Bellomo R. Correction and control of hyperammonemia in acute liver failure: the impact of continuous renal replacement timing, intensity, and duration. Crit Care Med [Internet]. 2020 [cited 2024 Jan 14];48(2):218–24. Available from: https://pubmed.ncbi.nlm.nih.gov/31939790/

46.

Verma N, Dhiman RK, Choudhury A, Taneja S, Duseja A, Singh V, et al. Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure. Hepatol Int [Internet]. 2021;15(4):970–82. https://doi.org/10.1007/s12072-021-10221-7.CrossRefPubMed

47.

Dong V, Robinson AM, Dionne JC, Cardoso FS, Rewa OG, Karvellas CJ. Continuous renal replacement therapy and survival in acute liver failure: a systematic review and meta-analysis. J Crit Care. 2024;81:154513.

48.

Shingina A, Mukhtar N, Wakim-Fleming J, Alqahtani S, Wong RJ, Limketkai BN, et al. Acute liver failure guidelines. Am J Gastroenterol. 2023;118(7):1128–53.

49.

Méndez-Guerrero O, Calle-Rodas DA, Cervantes-Alvarez E, Alatorre-Arenas E, Pérez-Escobar J, Navarro-Alvarez N, et al. Renal and brain failure predict mortality of patients with acute-on-chronic liver failure admitted to the intensive care unit. Ann Hepatol [Internet]. 2021 [cited 2024 Jan 14]; 22. Available from: https://pubmed.ncbi.nlm.nih.gov/33091594/

50.

Caracuel L, Sastre E, Callejo M, Rodrigues-Díez R, García-Redondo AB, Prieto I, et al. Hepatic encephalopathy-associated cerebral vasculopathy in acute-on-chronic liver failure: alterations on endothelial factor release and influence on cerebrovascular function. Front Physiol. 2020;20(11):593371.CrossRef

51.

Bajaj JS, O’Leary JG, Lai JC, Wong F, Long MD, Wong RJ, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022;117(2):225–52.

52.

Mikkelsen ACD, Kjærgaard K, Mookerjee RP, Vilstrup H, Wegener G, Bay-Richter C, et al. Non-alcoholic fatty liver disease: also a disease of the brain? A systematic review of the preclinical evidence. Neurochem Res [Internet]. 2022 [cited 2023 Dec 26]; Available from: https://pubmed.ncbi.nlm.nih.gov/35230646/

53.

Cushman M, Callas PW, Alexander KS, Wadley V, Zakai NA, Lidofsky SD, et al. Nonalcoholic fatty liver disease and cognitive impairment: a prospective cohort study. PLoS One [Internet]. 2023;18(4):e0282633. https://doi.org/10.1371/journal.pone.0282633.CrossRefPubMed

54.

Tan CH, Chang MC, Tsai WF, Chuang WL, Huang JF, Lin ZY, et al. Different profiles of neurocognitive impairment in patients with hepatitis B and C virus infections. Sci Reports 2022 121 [Internet]. 2022 [cited 2024 Jan 15];12(1):1–11. Available from: https://www.nature.com/articles/s41598-022-14736-3

55.

Kaur H, Dhiman RK, Kulkarni AV, Premkumar M, Singh V, Duseja AK, et al. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: a real-world cohort study. J Viral Hepat [Internet]. 2022;29(5):395–406. https://doi.org/10.1111/jvh.13668.CrossRefPubMed

56.

Ibáñez-Samaniego L, Rapado-Castro M, Cabrero L, Navarrete C, García-Mulas S, Ahumada A, et al. Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: a prospective real-life study. Eur J Neurol [Internet]. 2022;29(2):400–12. https://doi.org/10.1111/ene.15138.CrossRefPubMed

57.

Gioia S, Nardelli S, Riggio O, Faccioli J, Ridola L. Cognitive impairement in non-cirrhotic portal hypertension: highlights on physiopathology, diagnosis and management. J Clin Med [Internet]. 2022 [cited 2024 Jan 15];11(1):101. Available from: /pmc/articles/PMC8745274/

58.

Montagnese S, Rautou PE, Romero-Gómez M, Larsen FS, Shawcross DL, Thabut D, et al. EASL clinical practice guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807–24.

59.

Roy A, Giri S, Singh A, Vaidya A, Angadi S. Prophylactic lactulose therapy in patients with cirrhosis and upper gastrointestinal bleeding: a meta-analysis of randomized trials. J Gastrointestin Liver Dis [Internet]. 2023 [cited 2024 Jan 17];32(4):507–12. Available from: https://pubmed.ncbi.nlm.nih.gov/38147599/

60.

Tapper EB, Ospina E, Salim N, Chen X, Nikirk S. Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient-reported outcomes: the Mi-Kristal trial. Hepatology. 2023;78(4):1159–67.

61.

Bureau C, Thabut D, Jezequel C, Archambeaud I, D’Alteroche L, Dharancy S, et al. The Use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Ann Intern Med. 2021;174(5):633–40. https://doi.org/10.7326/M20-0202.CrossRefPubMed

62.

Kulkarni AV, Avadhanam M, Karandikar P, Rakam K, Gupta A, Simhadri V, et al. Antibiotics with or without rifaximin for acute hepatic encephalopathy in critically Ill patients with cirrhosis: a double-blind, randomized controlled (ARiE) trial. Am J Gastroenterol. 2022;10–4309.

63.

Moon AM, Kim HP, Jiang Y, Lupu G, Bissram JS, Barritt AS, et al. Systematic review and meta-analysis on the effects of lactulose and rifaximin on patient-reported outcomes in hepatic encephalopathy. Am J Gastroenterol. 2023;118(2):284–93.

64.

Hoilat GJ, Ayas MF, Hoilat JN, Abu-Zaid A, Durer C, Durer S, et al. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis. BMJ open Gastroenterol [Internet]. 2021 [cited 2023 Dec 26];8(1). Available from: https://pubmed.ncbi.nlm.nih.gov/34006606/

65.

Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial. Hepatology [Internet]. 2022 [cited 2024 Jan 14];75(5):1194–203. Available from: https://pubmed.ncbi.nlm.nih.gov/34822189/

66.

Fagan A, Gavis EA, Gallagher ML, Mousel T, Davis B, Puri P, et al. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study. J Hepatol. 2023;78(2):312–21.CrossRefPubMed

67.

Teh KB, Loo JH, Tam YC, Wong YJ. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: a systematic review and meta-analysis. Dig Liver Dis. 2021;53(7):817–23.CrossRefPubMed

68.

Mehtani R, Premkumar M, Garg S, Kajal K, Kulkarni A V., Soni SL, et al. Intravenous BCAA Infusion Does Not Lead to a Sustained Recovery From Overt HE in ACLF–An Open Label Randomized Clinical Trial. J Clin Exp Hepatology. 2023 Nov 1;13(6):977.

69.

Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology [Internet]. 2017 [cited 2024 Jan 17];66(6):1727–38. Available from: https://pubmed.ncbi.nlm.nih.gov/28586116/

70.

Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. gastroenterology [Internet]. 2019 [cited 2024 Jan 17];156(6):1921–1923.e3. Available from: https://pubmed.ncbi.nlm.nih.gov/30664879/

71.

Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology [Internet]. 2019 [cited 2024 Jan 17];70(5):1690–703. Available from: https://pubmed.ncbi.nlm.nih.gov/31038755/

72.

Sharma A, Roy A, Premkumar M, Verma N, Duseja A, Taneja S, et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol Int [Internet]. 2022 [cited 2024 Jan 17];16(2):433–46. Available from: https://pubmed.ncbi.nlm.nih.gov/35349076/

73.

Mukund A, Chalamarla LK, Singla N, Shasthry SM, Sarin SK. Intractable hepatic encephalopathy in cirrhotic patients: mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration. Eur Radiol [Internet]. 2020;30(6):3462–72. https://doi.org/10.1007/s00330-019-06644-4.CrossRefPubMed

74.

Rathi S, Kalantri A, Shastri A, Shree R, Mahesh KV, Taneja S, et al. Endoscopic ultrasound-guided transgastric shunt obliteration for recurrent hepatic encephalopathy. Am J Gastroenterol [Internet]. 2023 [cited 2024 Jan 15];118(10):1895–8. Available from: https://pubmed.ncbi.nlm.nih.gov/37589493/

75.

Yang M, Qiu Y, Wang W. Concurrent spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a systematic review and meta-analysis. Dig Liver Dis. 2023;10:013.

76.

Dudek P, Andruszkiewicz P, Gelo R, Badenes R, Bilotta F. Cerebral diseases in liver transplant recipients: systematic review of clinical evidence. J Clin Med [Internet]. 2022 [cited 2023 Dec 26];11(4). Available from: https://pubmed.ncbi.nlm.nih.gov/35207251/

77.

López-Franco Ó, Morin JP, Cortés-Sol A, Molina-Jiménez T, Del Moral DI, Flores-Muñoz M, et al. Cognitive impairment after resolution of hepatic encephalopathy: a systematic review and meta-analysis. Front Neurosci [Internet]. 2021 [cited 2023 Dec 27];15. Available from: https://pubmed.ncbi.nlm.nih.gov/33790729/

Titel: Liver and Brain Disorders
verfasst von: Akash Roy
Uday Chand Ghoshal
Mahesh K. Goenka
Publikationsdatum: 02.04.2024
Verlag: Springer US
Erschienen in: Current Hepatology Reports
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00668-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen